Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. - Wikidata - awgldk - TriplyDB

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.

http://www.wikidata.org/entity/Q38717239

about

BRCA population screening for predicting breast cancer: for or against?Coming of age in Canada: a study of population-based genetic testing for breast and ovarian cancer.The Promise and Practice of Genetics on Diabetes Care: The Fog Rises to Reveal a Field of Genetic Complexity in HNF1B.Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell Lines.What Happens After Menopause? (WHAM): protocol for a prospective, multicentre, age-matched cohort trial of risk-reducing bilateral salpingo-oophorectomy in high-risk premenopausal women.Metabolic Activity of Normal Glandular Tissue on 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Correlation with Menstrual Cycles and Parenchymal Enhancements.The Search for Biomarkers in Hereditary Angioedema.High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.Fertility preservation in BRCA-mutated women: when and how?Are VNTRs co-localizing with breast cancer-associated SNPs?Mutations in context: implications of BRCA testing in diverse populations.Genetic testing in women with breast cancer: implications for treatment.Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time?Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations.Genetic variation in the NEIL2 DNA glycosylase gene is associated with oxidative DNA damage in BRCA2 mutation carriers.Women with hereditary breast cancer predispositions should avoid using their smartphones, tablets, and laptops at night.Patient-Centered Care in Breast Cancer Genetic Clinics.Observed frequency and challenges of variant reclassification in a hereditary cancer clinic.The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy.Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review.Prophylactic mastectomy for BRCA mutation carriers after ovarian cancer treatment: is it beneficial?Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer.PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.The bidirectional association among female hormone-related cancers: breast, ovary, and uterine corpus.The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer.Genetics: BRCA-mutant breast/ovarian cancer revealed.Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data.Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision.Patterns of Occurrence and Outcomes of Contralateral Breast Cancer: Analysis of SEER Data.Development and Validation of Nomograms for Predicting Overall and Breast Cancer-Specific Survival in Young Women with Breast Cancer: A Population-Based Study Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition BRCA1/2 testing: therapeutic implications for breast cancer management Overview of Breast Cancer Therapy Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis Modifiable Lifestyle Factors: Opportunities for (Hereditary) Breast Cancer Prevention - a Narrative Review Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap The 10th Oxbridge varsity medical ethics debate-should we fear the rise of direct-to-consumer genetic testing?A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy

P2860

Q41050195-59798FB9-5BE0-4A72-A61A-30FC2A5B82A5 Q44323635-EBEF72A3-D27E-4D23-9EC8-4E1629DD12C6 Q45070793-57621ED1-D801-48AC-95B3-700480CE3FE5 Q47097943-F829E0A8-F45C-4B6F-82F8-477CA9572BD4 Q47127058-AC8ED49D-01BC-4060-AAC2-C304B0ECF26B Q47135256-EE11972F-33FC-4F44-8AF5-395EC245A502 Q47139750-3EB2DC30-8B6D-4425-9850-FE5DABFE63B6 Q47216242-144F709A-0697-49D1-9F50-2BD16126125F Q47554393-FC8B21A8-7E22-4D2D-B893-5E3604A22572 Q47564486-E99CC9C0-9EE4-40A2-B8CF-1A511CC8BD8E Q47691368-2F4F3957-23FE-4D4C-A8AC-8A0A3272AB2B Q47884776-20A30D23-C91A-4ADD-B2A2-24260BE663C8 Q48506802-6958CD5F-D211-46A8-8BC9-A6E80BD53661 Q49024646-6EE7E2DE-8A19-49B7-AE9C-2CF977936EC3 Q49569666-E8FB5949-B547-471E-AACB-B2160C7E4B50 Q49874321-AA28C6F2-CE72-4A8C-9011-15162A5EAF04 Q50033737-FC90F45F-0A02-4F58-8EB9-3B2F3520EFCF Q50033931-5285A3BA-3EB9-4EDD-949D-854ED0584DD7 Q50072706-C7210477-9E67-42FA-9FFC-A1E790D856E8 Q50091589-A071A93D-1D4C-4617-9B51-52AE981EDB29 Q50141660-09A49237-784D-4729-9372-72C2700A1A7B Q51764547-125ED5D1-89CF-4083-9571-F4DDD2BB7DBC Q52585367-6F66675B-9DEC-4F94-A0E7-F42537A6768A Q52586345-1573B486-3032-4EA1-9A69-078F61D8A2AF Q52684293-3A6D2D3B-824D-445E-8783-881BF97460B8 Q52715788-B2DCD8C1-00D9-40D9-A987-BA41F4BF8970 Q53738438-091C43E0-587C-49F0-B91D-B8C40145DBDE Q54950358-4F851D2C-035F-40F4-A889-0C927A1DBDFB Q54956851-E32EC571-04AA-443B-A7F0-D26EAB9CBCA1 Q55515741-CEF20124-C26D-4DA7-B470-6810C42563D6 Q56761470-7728C981-91C3-4AF8-B8A0-53E5FD1F0FD6 Q57054864-76C68373-F193-4131-8246-0AA2557A18B6 Q57110101-C9C0E3B9-6894-4506-96D7-C7619F31D287 Q57110718-79324E73-E830-4C3B-8E61-87219A9E8CB5 Q57112840-377F908A-8701-48FE-A407-856CE3DC51E2 Q57113809-F2CFBDD9-9186-4E05-9FF7-B3ECA9C94B9D Q57420847-DFCA5B01-70CF-478F-9E76-8A45CDE84F60 Q57907545-EDC27041-4711-4B1E-9812-60AEE76ED9DD Q58106428-5CCA0560-445C-47E1-B2C9-6BC03C272001 Q58580413-C030D902-444C-4D23-ADAA-2B1EB6900F78

P2860

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.

http://www.wikidata.org/entity/Q38717239

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Risks of Breast, Ovarian, and ...... 1 and BRCA2 Mutation Carriers.

@en

Risks of Breast, Ovarian, and ...... 1 and BRCA2 Mutation Carriers.

@en-gb

type

label

Risks of Breast, Ovarian, and ...... 1 and BRCA2 Mutation Carriers.

@en

Risks of Breast, Ovarian, and ...... 1 and BRCA2 Mutation Carriers.

@en-gb

prefLabel

Risks of Breast, Ovarian, and ...... 1 and BRCA2 Mutation Carriers.

@en

Risks of Breast, Ovarian, and ...... 1 and BRCA2 Mutation Carriers.

@en-gb

P1433

Q38717239-C6F0C54C-91BA-47CF-B7BD-A38958E7C782

P1476

Q38717239-854722B3-9F16-4B4C-87BA-54FF0247230A

P2093

Q38717239-015300C4-B96B-486D-BC20-F0218D64B0BA

Q38717239-06F28D7B-A414-4DBD-9518-A91E10E9CC1F

Q38717239-0937977C-9F34-4B8D-A5E2-BF5775B438EA

Q38717239-0E1087FD-39E9-4D51-8714-A98115ACFC9E

Q38717239-101E0602-7BDE-4FA4-8670-38392582F1B3

Q38717239-15412AEB-4EED-47A6-BD77-80B24381BCBC

Q38717239-1C256D41-6D84-480D-9CF0-C8AE20E90961

Q38717239-406D7F8D-AB52-4472-AF36-AE12B67B12AE

Q38717239-45893052-F9AF-4340-A5B2-90485FC0B849

Q38717239-487F8D56-9CFA-469D-BEE3-2CEA28D09414

P304

Q38717239-DB381EE2-C83B-4C69-86DB-2FCC8A454169

P31

Q38717239-8CA1FDBD-1796-427A-BC64-EE6F26DFEC95

P356

Q38717239-2E5FAD43-84D0-4393-9B17-EADB9BB94D60

P407

Q38717239-6046D824-8C66-4CBF-8B19-335F74FA86F6

P433

Q38717239-2BDBC0CF-B3DF-42D2-8CC1-6322C763539D

P478

Q38717239-41A3F73C-2D82-404B-BED6-651626CF2AC2

P50

Q38717239-02421AE4-13B7-4FF0-8A76-C01979A94D2C

Q38717239-06E608A0-D7ED-4CAA-8B10-CADCB657A832

Q38717239-0B609913-BF85-4C43-8382-300566F0EE06

Q38717239-140EEE47-3BE8-4A67-8A4C-0860FAEF4E43

Q38717239-168063FA-6256-4AA4-9A24-FA6145AF4DC5

Q38717239-1DA82A03-0618-4F10-A007-2B1568E175FB

Q38717239-37CC967A-72D8-492F-B472-6EE4D3E95325

Q38717239-48C0E696-C2E4-46BF-AE71-F33A73422D89

Q38717239-5724E20A-2D39-49C7-8796-B3125FAF76CA

Q38717239-5B4B9D5C-CEFF-438F-B40C-F28CF2E4944C

P577

Q38717239-EFD3233E-F9F9-470B-8874-FD3FB4DCEE81

P698

Q38717239-9A755577-2731-4414-8F46-958E58D1B8F1

P356

P1433

Journal of the American Medical Association

P1476

Risks of Breast, Ovarian, and ...... 1 and BRCA2 Mutation Carriers.

@en

P2093

Ana Osorio

http://www.w3.org/2001/XMLSchema#string

BRCA1 and BRCA2 Cohort Consortium

http://www.w3.org/2001/XMLSchema#string

Brita Arver

http://www.w3.org/2001/XMLSchema#string

Carolien M Kets

http://www.w3.org/2001/XMLSchema#string

Catherine Nogues

http://www.w3.org/2001/XMLSchema#string

Christian F Singer

http://www.w3.org/2001/XMLSchema#string

Christine Lasset

http://www.w3.org/2001/XMLSchema#string

David E Goldgar

http://www.w3.org/2001/XMLSchema#string

Edith Olah

http://www.w3.org/2001/XMLSchema#string

Eva Machackova

http://www.w3.org/2001/XMLSchema#string

P304

2402-2416

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2017.7112

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

317

http://www.w3.org/2001/XMLSchema#string

P50

Shirley Hodgson

Dominique Stoppa-Lyonnet

Rita Schmutzler

Lenka Foretová

Julian Weldon Adlard

Anne-Marie Gerdes

Melissa C. Southey

Christoph Engel

P577

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28632866

http://www.w3.org/2001/XMLSchema#string